Entrada Therapeutics Names Linea Aspesi as Chief People Officer
News related to:Entrada Therapeutics · 1 min read
BOSTON, Oct. 21, 2026 /CourierPR/ -- Entrada Therapeutics, a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines, has appointed Linea Aspesi as its Chief People Officer. This move comes at a critical time for the company, as it advances its pipeline of potential treatments for neuromuscular and inherited retinal diseases.
Ms. Aspesi, an organizational leader with more than twenty years of experience driving culture transformation at biopharmaceutical and technology companies ranging from small-cap to Fortune 500, is excited to join the team at such an important time in Entrada's growth.
Prior to joining Entrada, Ms. Aspesi served as Chief People Officer at KalVista Pharmaceuticals, which was acquired by Chiesi Group. She has also held executive-level human resources leadership roles at several life science companies, including Editas Medicine, Forma Therapeutics, Inc. (acquired by Novo Nordisk), Saniona, Inc., Sobi, Inc., and Genzyme Biologics Manufacturing (acquired by Sanofi). Her experience spans a wide range of organizations, with a particular focus on scaling companies from discovery through commercial stages. Aspesi's expertise in culture transformation and employee engagement is expected to be instrumental in driving the company's mission to transform the lives of patients by establishing a new class of genetic medicines.
Entrada Therapeutics is currently advancing its lead oligonucleotide programs for the potential treatment of Duchenne muscular dystrophy, specifically targeting exon 44, 45, 50, and 51. Additionally, the company has partnered to develop a clinical-stage program, VX-670, for the treatment of myotonic dystrophy type 1. The company's approach is based on proprietary, versatile, and modular approaches, enabling the advancement of a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others.
The company's commitment to patients and its strong, mission-driven culture are key drivers of its success, and Aspesi's appointment is expected to further strengthen these attributes.